We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




New Genetic Risk Factors Identified for Peanut Allergy

By LabMedica International staff writers
Posted on 25 Oct 2017
Peanut allergy develops in early life and is rarely outgrown. More...
Roughly 1% of Canadian adults and between 2% and 3% of Canadian children are affected, and the symptoms can be severe and even life threatening.

A new gene associated with peanut allergy has been revealed, offering further evidence that genes play a role in the development of food allergies and opening the door to future studies, improved diagnostics and new treatment options.

An international team of scientists collaborating with those at the University of British Columbia (Vancouver, BC, Canada) scanned more than 7.5 million genetic locations in the DNA of 850 people with peanut allergy and nearly 1,000 people without it, through a genome-wide association study (GWAS), to search for markers that might be linked to food allergy. They recruited the peanut allergy participants from the Canadian Peanut Allergy Registry. The team also conducted a fresh analysis of results pooled from six other genetic studies of populations in North America, Australia, Germany, and the Netherlands. Genotyping of 1,974 individuals (987 cases, 987 controls) was conducted on the Illumina Omni 2.5M+Exome 8v1.1 chip.

The scientists reported that their study is the first to associate the EMSY, BRCA2 Interacting Transcriptional Repressor (EMSY) locus with food allergy, and these findings suggest that the gene plays an important role in the development of not just food allergy but also general allergic predisposition. The gene, called c11orf30/EMSY (EMSY), is already known to play a role in other allergy-related conditions, such as eczema, asthma, and allergic rhinitis. The team also found evidence that five other genetic locations might be involved.

Denise Daley, PhD, an associate professor and senior author of the study, said, “Food allergy is the result of both genetic and environmental factors, but there are surprisingly few data regarding the genetic basis of this condition. The discovery of this genetic link gives us a fuller picture of the causes of food allergies, and this could eventually help doctors identify children at risk.” The study was published on November 10, 2017, in the Journal of Allergy and Clinical Immunology.

Related Links:
University of British Columbia


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.